← Human Trials & Peer-Reviewed Studies
Continuous subcutaneous rhPTH infusion for managing difficult chronic hypoparathyroidism. A systematic review.
Plain-language guide to PMID 37017857 (2023): systematic review of Teriparatide and Parathyroid Hormone (PTH 1-84), chronic and systemic inflammation.
Key Facts
- PMID
- 37017857
- Journal
- Endocrine
- Year
- 2023
- Study type
- Systematic Review
- Authors
- Gamarra E et al. (7 authors)
- DOI
- 10.1007/s12020-023-03355-1
What This Paper Covers, in Plain Language
What It Covers
This systematic review looks at Teriparatide and Parathyroid Hormone (PTH 1-84) in the context of chronic and systemic inflammation.
Standard treatment for chronic hypoparathyroidism is represented by long-life per os supplementation of calcium and vitamin D.
Since 90s, exogenous PTH is also available, but a not negligible number of patients experience a poor control.
Starting from the experience with pumps in diabetes, it has been hypothesized that the infusion of PTH through pump might result in a better disease control.
Who the Included Studies Covered
The age groups tagged for this paper are children and adults.
How the Review Was Done
A comprehensive computer literature search of the PubMed/MEDLINE, Embase, and Scopus databases was conducted by two authors independently (last search on November 30, 2022).
All findings were summarized and critically discussed.
What Was Measured
The subject headings attached to it are Parathyroid Hormone, Hypoparathyroidism, Calcium, Vitamin D and Infusions, Subcutaneous.
The authors tagged it with the keywords Hypocalcemia, Insulin pump and Systematic review.
What This Means in Plain Language
This is a systematic review of Teriparatide and Parathyroid Hormone (PTH 1-84) in people with chronic and systemic inflammation.
The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2023 (Endocrine), a journal based in United States.
More context: the Teriparatide compound page and the Parathyroid Hormone (PTH 1-84) compound page, Chronic and systemic inflammation research.
Our Notes on the Compounds
Teriparatide: A parathyroid hormone fragment, PTH(1-34), with human trials and approved-pen labeling; the research vial is not the approved pen.
Parathyroid Hormone (PTH 1-84): The 84-amino-acid hormone that raises blood calcium; full-length PTH (Natpara) has been used in hypoparathyroidism. Teriparatide is its 1-34 fragment.
Related Pages
- Chronic and systemic inflammation research
- Teriparatide in the library
- Parathyroid Hormone (PTH 1-84) in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.